News & Events

You are here

Asia-Pacific specialist CRO Novotech presented Australia's R&D Refund and Simplified Regulatory Environment as a Gateway to Asia at a Government and industry event in Seoul, South Korea.


Novotech signs MOU with South Korea’s leading medical center, the Asan Medical Center

15 April 2017, Sydney, Australia and Seoul, Korea: Asia Pacific specialist CRO Novotech announced today it has signed a Memorandum of Understanding (MOU) with South Korea’s largest medical institution – The Asan Medical Center’s...


New Frost & Sullivan research reveals Asia as Preferred Destination for Clinical Trials


1 March 2017, Sydney, Australia: Frost & Sullivan today released its latest white paper, ‘Asia: Preferred Destination for Clinical Trials’, with Asia Pacific specialist CRO Novotech. Research...


Novotech Update: 8 reasons why China should be your next clinical trial destination

Happy Chinese New Year!
While China has long been a key powerhouse in Asia, its trajectory over the next decade is set to sky rocket. 

Here are 8 top facts you need to know about China’s growing economy and...


Novotech Update: 8 reasons why Australia should be your next clinical trial destination

Australia is internationally recognised for its superior clinical research and healthcare infrastructure, world-class research capabilities and highly killed researchers. All critical prerequisites for early phase clinical trials...


Novotech Update: Novotech and Deloitte brief biotech companies on benefits of accessing Australia’s R&D scheme


10 January 2017; San Francisco, California, United States: At a private event during this year’s JP Morgan conference, Novotech and Deloitte briefed international biotech companies on how to access...


Novotech Update: Novotech presents to Chinese biotechs on 3 key benefits of early stage clinical trials in Australia

Novotech presented to a number of biotechnology companies based at China’s SuZhou BioBay industrial...


Novotech recognised as Asia Pacific growth leader by Frost & Sullivan research analysts

Sydney, Australia: Leading Asia Pacific CRO Novotech has won the Clinical Research Organisation (CRO) Growth Excellence Leadership award in...


Novotech announces transition of CEO role

Novotech announces transition of CEO role from Alek Safarian to John Moller, effective 23rd January 2017. Currently based in Novotech’s Singapore office, Dr Moller joined Novotech as Chief Operating Officer, Asia, in January 2014 and has overseen...


Novotech Update: Novotech and Deloitte Launch U.S. Biotech Briefings about 60% Savings for Early Phase Clinical Trials in Australia

Sydney, Australia – October 27, 2016: In an industry first Novotech and Deloitte have teamed up to brief U.S. CFOs of early stage companies about Australian tax breaks for early phase clinical trials. 

New research from...


Download Whitepaper - Australia: Preferred Destination for Early Phase Clinical Trials (A Frost and Sullivan White Paper)


Click here to download the Frost and Sullivan whitepaper to learn more about the benefits of running early phase trials in Australia.